TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11925053

Group type: EXPERIMENTAL
Intervention: Twelve Step Facilitation
Number of subjects: 952

Group type: COMPARATOR
Intervention: Motivational Enhancement Therapy
Number of subjects: 952

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 952
Study: 9389394

Group type: EXPERIMENTAL
Intervention: Intradermal sutures
Number of subjects: 242

Group type: COMPARATOR
Intervention: Staples
Number of subjects: 242
Study: 7874150

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (swimmers)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Anaerobic exercise (wrestlers)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 18
Study: 3061557

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 11391690

Group type: EXPERIMENTAL
Intervention: Long-term survivor mixture model with random effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalized linear mixed model (GLMM) approach
Number of subjects: 0
Study: 31564523

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30087427

Group type: EXPERIMENTAL
Intervention: High dose PORT (>66.60 cGy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Very high dose PORT (>70.20 cGy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community centers treatment
Number of subjects: 0
Study: 26879896

Group type: EXPERIMENTAL
Intervention: ViSC Social Competence Program
Number of subjects: 2042
Study: 25259553

Group type: EXPERIMENTAL
Intervention: Minilaparotomy cholecystectomy (MC)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 88
Study: 22745114

Group type: EXPERIMENTAL
Intervention: D5W-LA group (6 mL of D5W followed by 6 mL of lidocaine 1.5% with epinephrine 1:200,000)
Number of subjects: 95

Group type: COMPARATOR
Intervention: LA group (6 mL of lidocaine 1.5% with epinephrine 1:200,000 alone)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: D5W-LA group
Number of subjects: 95

Group type: COMPARATOR
Intervention: LA group
Number of subjects: 95
Study: 19967762

Group type: EXPERIMENTAL
Intervention: Cook‐Swartz implantable Doppler probe
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clinical monitoring alone
Number of subjects: 40
Study: 21475452

Group type: EXPERIMENTAL
Intervention: El-Menia air inflated balloon
Number of subjects: 240

Group type: COMPARATOR
Intervention: Ecbolics and uterine massage (Control)
Number of subjects: 240
Study: 14990557

Group type: EXPERIMENTAL
Intervention: Hypohydrated + Water ad libitum (Hy+W)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Euhydrated + Water ad libitum (Eu+W)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hypohydrated + No Water (Hy+NW)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Euhydrated + No Water (Eu+NW)
Number of subjects: 10
Study: 11275671

Group type: EXPERIMENTAL
Intervention: 228‐ppm fluoride controlled‐release rinse (CR rinse)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 228‐ppm fluoride NaF rinse
Number of subjects: 13

Group type: COMPARATOR
Intervention: Water rinse
Number of subjects: 13
Study: 9870619

Group type: EXPERIMENTAL
Intervention: Passive head turning (70 degrees to either side)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Facing forward
Number of subjects: 16
Study: 8304603

Group type: EXPERIMENTAL
Intervention: Suprapubic bladder aspiration
Number of subjects: 100

Group type: COMPARATOR
Intervention: Urethral catheterization
Number of subjects: 100
Study: 2656736

Group type: EXPERIMENTAL
Intervention: Cabergoline 0.2-1 mg once weekly
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cabergoline 0.2-0.5 mg twice weekly
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cabergoline 0.4-0.6 mg three times weekly
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cabergoline 0.3-0.6 mg once weekly
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cabergoline 2-3 mg weekly
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cabergoline (various schedules)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 30939361

Group type: EXPERIMENTAL
Intervention: AUT00063 (800 mg capsules daily for 28 days)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 28089564

Group type: EXPERIMENTAL
Intervention: Peak oxygen consumption (VO2peak) measured in a symptom‐limited ramp exercise test
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Age and sex factors
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: History of cardiovascular disease and pulmonary disease
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Physical activity level, hypertension, smoking, and overweight
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: History of stroke and stroke characteristics
Number of subjects: 113
Study: 25727860

Group type: EXPERIMENTAL
Intervention: Sildenafil 20, 40 or 80 mg three times daily
Number of subjects: 277

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: eGFR <60 ml min(‐1) 1.73 m(‐2)
Number of subjects: 277
Study: 23259764

Group type: EXPERIMENTAL
Intervention: Meal 1 (50g CH, 8.9g fat, 3.3g protein)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Meal 2 (50g CH, 37.4g fat, 28.9g protein)
Number of subjects: 17
Study: 20828634

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) delivered via telephone, 6 sessions
Number of subjects: 216

Group type: COMPARATOR
Intervention: Attention control group (details not specified)
Number of subjects: 216
Study: 18579168

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.03 g/kg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 16899034

Group type: EXPERIMENTAL
Intervention: Alcohol Urge Questionnaire (AUQ) under neutral conditions
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Alcohol Urge Questionnaire (AUQ) during cue-elicited urge state
Number of subjects: 248
Study: 15085979

Group type: EXPERIMENTAL
Intervention: Rimexolone 1% ophthalmic suspension (27 subjects)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Prednisolone acetate 1% (21 subjects)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Rimexolone 1% ophthalmic suspension
Number of subjects: 48

Group type: COMPARATOR
Intervention: Prednisolone acetate 1%
Number of subjects: 48
Study: 10686218

Group type: COMPARATOR
Intervention: 600 mg testosterone alone (T; n = 11)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 10 mg oestradiol (TE10; n = 7)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 20 mg oestradiol (TE20; n = 8)
Number of subjects: 26
Study: 10165315

Group type: EXPERIMENTAL
Intervention: Famciclovir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acyclovir
Number of subjects: 0
Study: 8374686

Group type: EXPERIMENTAL
Intervention: rhGH therapy administered 3 times a week with a total weekly dose of 0.5 IU/kg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: rhGH therapy administered 6 times a week with a total weekly dose of 0.5 IU/kg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D3 (1.5 micrograms/day for 4 days)
Number of subjects: 22
Study: 3529360

Group type: EXPERIMENTAL
Intervention: Cimetidine, 1 g/day for 4 weeks (C4)
Number of subjects: 48

Group type: COMPARATOR
Intervention: 1 week of cimetidine treatment followed by 3 weeks of placebo (C1 + P)
Number of subjects: 48

Group type: COMPARATOR
Intervention: C1 + P
Number of subjects: 48
Study: 28328086

Group type: EXPERIMENTAL
Intervention: Experimental treatment condition (EXP; N = 11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Treatment-as-usual control condition (TAU; N = 10)
Number of subjects: 21
Study: 26439386

Group type: COMPARATOR
Intervention: OFD + placebo gel (group 1)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: PRF + HA with OFD (group 2)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 1.2 mg RSV gel + PRF + HA with OFD (group 3)
Number of subjects: 105
Study: 25089930

Group type: EXPERIMENTAL
Intervention: Sequential fluoxetine (16-week course initiated 8 weeks prequit)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Sequential fluoxetine
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study: 22048712

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (30 min of supervised cycle training at 65% of VO(2max), three times per week for 4 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (maintaining normal levels of physical activity)
Number of subjects: 30
Study: 19561363

Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 208
Study: 18401673

Group type: EXPERIMENTAL
Intervention: Tailored newsletters based on self-determination theory (SDT) and motivational interviewing (MI) principles
Number of subjects: 512

Group type: COMPARATOR
Intervention: Control newsletters tailored only on demographic and social cognitive variables
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Experimental group (younger participants)
Number of subjects: 512

Group type: COMPARATOR
Intervention: Control group (younger participants)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Experimental group (older participants)
Number of subjects: 512

Group type: COMPARATOR
Intervention: Control group (older participants)
Number of subjects: 512
Study: 15793249

Group type: EXPERIMENTAL
Intervention: Pramlintide (30-45 microg) with usual insulin bolus-to-carbohydrate ratio
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Increased insulin bolus-to-carbohydrate ratio with minidose glucagon rescue injections
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control subjects (no intervention)
Number of subjects: 8
Study: 15046689

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg every 3 weeks for 15 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10630070

Group type: EXPERIMENTAL
Intervention: Topical application of mesoglycan (1 or 2 vials/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vegetal stimulins (control group)
Number of subjects: 40
Study: 7498384

Group type: EXPERIMENTAL
Intervention: Conical contact pad
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flat contact pad
Number of subjects: 0
Study: 2127834

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg twice daily for 28 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 20
Study: 7194395

Group type: EXPERIMENTAL
Intervention: Infusion of 150 ml/kg per day
Number of subjects: 28

Group type: COMPARATOR
Intervention: Infusion of 60 ml/kg per day
Number of subjects: 28
Study: 30852278

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 27810317

Group type: EXPERIMENTAL
Intervention: XG-102 900 μg
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: XG-102 90 μg
Number of subjects: 145

Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 145
Study: 26218050

Group type: EXPERIMENTAL
Intervention: ChannelFree (CF) processing
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Wide Dynamic Range Compression (WDRC) processing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unaided condition
Number of subjects: 20
Study: 23695545

Group type: COMPARATOR
Intervention: Standard triple therapy (omeprazole 20 mg bid + amoxicillin 1 g bid + clarithromycin 500 mg bid for 7 days)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Sequential therapy (omeprazole 20 mg bid + amoxicillin 1 g bid for 5 days, followed by omeprazole 20 mg bid + tinidazole 500 mg bid + clarithromycin 500 mg bid for an additional 5 days)
Number of subjects: 281
Study: 21292420

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) therapy for an average of 6.6 years
Number of subjects: 513

Group type: COMPARATOR
Intervention: Control group (nonusers of CEE therapy)
Number of subjects: 513
Study: 19052141

Group type: EXPERIMENTAL
Intervention: 10 mg methylphenidate
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 17466655

Group type: EXPERIMENTAL
Intervention: Nebulizer
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Concomitant treatment
Number of subjects: 140

Group type: COMPARATOR
Intervention: Inhaler
Number of subjects: 140
Study: 15238969

Group type: EXPERIMENTAL
Intervention: Appointment plus reminder
Number of subjects: 231

Group type: COMPARATOR
Intervention: Appointment only
Number of subjects: 231
Study: 11379675

Group type: EXPERIMENTAL
Intervention: 8 mg ropivacaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 8 mg ropivacaine plus 75 microg clonidine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 8 mg ropivacaine plus 15 microg clonidine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 8 mg ropivacaine plus 45 microg clonidine
Number of subjects: 120
Study: 9182213

Group type: COMPARATOR
Intervention: Zidovudine alone
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Didanosine alone
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Zidovudine plus didanosine
Number of subjects: 831
Study: 8351757

Group type: EXPERIMENTAL
Intervention: Maintenance Bacillus Calmette‐Guérin (BCG) therapy with 20 intravesical instillations in 1 year
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Maintenance Bacillus Calmette‐Guérin (BCG) therapy with 20 intravesical instillations in 1 year and 6 intradermal inoculations
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no intradermal inoculations)
Number of subjects: 49
Study: 3606929

Group type: EXPERIMENTAL
Intervention: Nifedipine infusion
Number of subjects: 17

Group type: COMPARATOR
Intervention: Vehicle infusion
Number of subjects: 17
Study: 2526573

Group type: EXPERIMENTAL
Intervention: Coronary bypass surgery
Number of subjects: 386

Group type: COMPARATOR
Intervention: No surgery (control group)
Number of subjects: 386
Study: 31471960

Group type: EXPERIMENTAL
Intervention: Authors' familiarity with predatory journals
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Awareness of Beall's list of predatory journals
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Belief about publication in a predatory journal
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Future publication intentions
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Lack of peer review awareness
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Editors' awareness of their journal listing
Number of subjects: 249
Study: 26119203

Group type: EXPERIMENTAL
Intervention: Percutaneous interspinous process spacer (IPS) treatment
Number of subjects: 80
Study: 23988791

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation for 12 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 21610482

Group type: EXPERIMENTAL
Intervention: Same-handed unit configuration
Number of subjects: 8

Group type: COMPARATOR
Intervention: Mirrored unit configuration
Number of subjects: 8
Study: 19620913

Group type: EXPERIMENTAL
Intervention: 3 whole body vibration sessions per week
Number of subjects: 73
Study: 16095786

Group type: EXPERIMENTAL
Intervention: Implementation intention intervention
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study: 15481651

Group type: EXPERIMENTAL
Intervention: kami-shoyo-san
Number of subjects: 113

Group type: COMPARATOR
Intervention: antidepressants
Number of subjects: 113
Study: 11747248

Group type: EXPERIMENTAL
Intervention: 200 microg of inhaled salbutamol (Albuterol) from the original Glaxo product
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 200 microg of inhaled salbutamol (Albuterol) from generic product 1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 200 microg of inhaled salbutamol (Albuterol) from generic product 2
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9242858

Group type: EXPERIMENTAL
Intervention: Occupational Adaptation intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control subjects (no intervention)
Number of subjects: 50
Study: 7506173

Group type: EXPERIMENTAL
Intervention: nimesulide 5 mg/kg/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: mefenamic acid 5 mg/kg divided into 2 or 3 daily doses
Number of subjects: 100
Study: 3813056

Group type: EXPERIMENTAL
Intervention: Isobaric 0.5% bupivacaine (3 ml)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hyperbaric 0.5% bupivacaine (3 ml)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study: 30897585

Group type: EXPERIMENTAL
Intervention: Music therapy (20 min before, during, and 20 min after endotracheal suctioning)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (routine suctioning)
Number of subjects: 98
Study: 29189539

Group type: EXPERIMENTAL
Intervention: Esmolol (0.25 mg/kg IV loading dose followed by 15 μg/kg/min infusion)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (normal saline infusion)
Number of subjects: 50
Study: 26825757

Group type: EXPERIMENTAL
Intervention: modified WHO ORS with PHGG 15 g/L
Number of subjects: 126

Group type: COMPARATOR
Intervention: modified WHO ORS without PHGG (control)
Number of subjects: 126
Study: 23648370

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22051585

Group type: EXPERIMENTAL
Intervention: Active interferential current
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (sham) interferential current
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 40
Study: 19092347

Group type: EXPERIMENTAL
Intervention: Heller laparoscopic myotomy plus anterior fundoplication (Dor procedure)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Heller laparoscopic myotomy plus total fundoplication (floppy-Nissen procedure)
Number of subjects: 144
Study: 16943652

Group type: EXPERIMENTAL
Intervention: Hypothermia therapy for 24 hours
Number of subjects: 39

Group type: COMPARATOR
Intervention: Pretrial clinical evaluation phase
Number of subjects: 39
Study: 14578238

Group type: EXPERIMENTAL
Intervention: DOIT (Diabetes Outpatient Intensive Treatment program)
Number of subjects: 167

Group type: COMPARATOR
Intervention: EDUPOST (standard diabetes care with quarterly educational mailings)
Number of subjects: 167
Study: 10343151

Group type: EXPERIMENTAL
Intervention: tolcapone (200 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 7498102

Group type: EXPERIMENTAL
Intervention: Low‐erucic acid rapeseed oil (RO)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sunflower oil (SO)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Butter oil (BO)
Number of subjects: 12
Study: 1941390

Group type: EXPERIMENTAL
Intervention: Ibuprofen 5 mg/kg
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Ibuprofen 10 mg/kg
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Ibuprofen (both dosages)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 178
Study: 7076005

Group type: EXPERIMENTAL
Intervention: Bedtime chenic acid plus low cholesterol diet
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bedtime chenic acid
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Conventional regimen of mealtime chenic acid
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 10
Study: 29721503

Group type: EXPERIMENTAL
Intervention: Radiofrequency current (RFC)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Cryoballoon
Number of subjects: 89
Study: 27514768

Group type: EXPERIMENTAL
Intervention: Zinc sulfate syrup plus routine treatment of UTI
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard treatment protocol for UTI
Number of subjects: 200
Study: 24933717

Group type: EXPERIMENTAL
Intervention: Oculomotor training (OMT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (P) training
Number of subjects: 12
Study: 21972797

Group type: EXPERIMENTAL
Intervention: Perception/cognition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Language-specific semantics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: English language
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Korean language
Number of subjects: 0
Study: 20032273

Group type: EXPERIMENTAL
Intervention: Women with greater self-esteem and presented with an alternative positive social identity (college students)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Women lower in self-esteem
Number of subjects: 0
Study: 18533934

Group type: EXPERIMENTAL
Intervention: Alfacarcidol (vitamin D)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alfacarcidol (vitamin D) + Risedronate (bisphosphonate)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Risedronate (bisphosphonate)
Number of subjects: 20
Study: 15777446

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study: 12439072

Group type: EXPERIMENTAL
Intervention: Group‐mediated cognitive‐behavioral intervention (GMCB)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Traditional cardiac rehabilitation (CRP)
Number of subjects: 147
Study: 9715775

Group type: EXPERIMENTAL
Intervention: Active compression-decompression CPR (ACD-B)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Active compression-decompression CPR (ACD-S)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 14
Study: 7707120

Group type: EXPERIMENTAL
Intervention: IFN/5‐FU (9 MIU interferon alfa-2a subcutaneously three times per week, 5‐FU 750 mg/m2/d by continuous intravenous infusion on days 1 to 5, then weekly i.v. bolus)
Number of subjects: 496

Group type: COMPARATOR
Intervention: LV/5‐FU (200 mg/m2/d leucovorin by i.v. infusion plus 5‐FU 370 mg/m2/d by i.v. bolus on days 1 to 5, repeated every 4 weeks)
Number of subjects: 496
Study: 2533034

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional injection therapy
Number of subjects: 30
Study: 335041

Group type: EXPERIMENTAL
Intervention: Povidone iodine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 0